{
  "id": "nsclc-biomarker",
  "display_name": "NSCLC Biomarker Testing",
  "cohort": "NSCLC, Biomarker Testing Compliance (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "NSCLC biomarker testing achieves 87% overall compliance, but with significant biomarker-specific variation: EGFR 95%, ALK 92%, PD-L1 90%, but ROS1 72%, MET 68%, and NTRK 45%.",
  "chart": {
    "type": "bar",
    "unit": "biomarker",
    "data": [
      { "name": "EGFR", "value": 95, "gap": 5, "highlight": false },
      { "name": "ALK", "value": 92, "gap": 2, "highlight": false },
      { "name": "PD-L1", "value": 90, "gap": 0, "highlight": false },
      { "name": "ROS1", "value": 72, "gap": -18, "highlight": true },
      { "name": "MET", "value": 68, "gap": -22, "highlight": true },
      { "name": "KRAS", "value": 76, "gap": -14, "highlight": false },
      { "name": "BRAF", "value": 78, "gap": -12, "highlight": false },
      { "name": "NTRK", "value": 45, "gap": -45, "highlight": true },
      { "name": "RET", "value": 64, "gap": -26, "highlight": true }
    ],
    "benchmark": 90,
    "nccn_target": 95
  },
  "financial_impact": {
    "annual_opportunity": "$365,000/year",
    "math": "$365,000/year = 25% avg testing gap (emerging biomarkers) × 42 eligible patients × $34,700 precision therapy value"
  },
  "clinical_impact": {
    "description": "Comprehensive NSCLC biomarker testing improves outcomes through expanded targeted therapy options.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+9.2 months",
        "description": "Improved progression-free survival with matched therapies"
      },
      {
        "type": "OS",
        "value": "+12.6 months",
        "description": "Overall survival benefit with biomarker-guided treatment"
      },
      {
        "type": "ORR",
        "value": "+47%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "QoL",
        "value": "+32%",
        "description": "Improved quality of life scores"
      },
      {
        "type": "Hosp",
        "value": "-38%",
        "description": "Reduced hospitalization rate"
      }
    ],
    "quantitative": "+12.6 months OS"
  },
  "peer_comparison": {
    "description": "Top-performing NSCLC programs achieve >90% comprehensive biomarker panel testing rates through reflex testing protocols.",
    "peer_benchmark": 90,
    "financial_impact": {
      "annual_opportunity": "$420,000/year",
      "math": "$420,000/year = 28% gap to peer benchmark × 48 patients × $31,500 improved care value"
    },
    "action_steps": [
      {
        "text": "Implement NSCLC-specific reflex molecular testing panel",
        "icon": "document"
      },
      {
        "text": "Create comprehensive testing protocol for all lung cancer patients",
        "icon": "clipboard"
      },
      {
        "text": "Develop automated biomarker tracking system",
        "icon": "chart"
      },
      {
        "text": "Establish NSCLC molecular tumor board",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 95,
  "action_steps": [
    {
      "text": "Implement comprehensive NGS panel as standard for all NSCLC",
      "icon": "document"
    },
    {
      "text": "Create provider education on emerging NSCLC biomarkers",
      "icon": "users"
    },
    {
      "text": "Develop liquid biopsy program for tissue-limited cases",
      "icon": "flask"
    },
    {
      "text": "Establish biomarker testing KPI tracking by provider",
      "icon": "chart"
    }
  ],
  "suggestions": [
    {
      "text": "Consider tissue preservation protocol optimization",
      "icon": "clipboard"
    },
    {
      "text": "Evaluate expanded RNA-based fusion testing",
      "icon": "search"
    }
  ],
  "drilldowns": [
    {
      "label": "By Provider",
      "cohort": "NSCLC Testing by Provider",
      "jsonFile": "nsclc-biomarker-by-provider.json",
      "drilldownLevel": 3
    },
    {
      "label": "By Testing Method",
      "cohort": "NSCLC Testing by Method",
      "jsonFile": "nsclc-biomarker-by-method.json",
      "drilldownLevel": 3
    },
    {
      "label": "All Biomarkers",
      "cohort": "Biomarker Testing by Cancer Type",
      "jsonFile": "biomarker-compliance-by-cancer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 